The Effect of Menopause on Antipsychotic Response

Overview

Journal Brain Sci

Publisher MDPI

Date 2022 Oct 27

PMID 36291276

Authors

Alexandre Gonzalez-Rodriguez

Jose A Monreal

Mary V Seeman

Affiliations

Soon will be listed here.

Abstract

Background: It has been hypothesized that, whenever estrogen levels decline, psychosis symptoms in women increase. At menopause, this can happen in two main ways: (a) the loss of estrogen (mainly estradiol) can directly affect central neurotransmission, leading to increase in schizophrenia-related symptoms, and (b) the loss of estrogen can decrease the synthesis of enzymes that metabolize antipsychotic drugs, thus weakening their efficacy. Aims and Methods: The aim of this narrative review was to investigate the second possibility by searching PubMed and ClinicalTrials.gov for studies over the last two decades that investigated the metabolism of antipsychotics and their efficacy before and after menopause in women or that studied systemic and local estrogen level effects on the pharmacokinetics and pharmacodynamics of individual antipsychotic drugs. Results: The evidence suggests that symptom level in women with schizophrenia rises after menopause for many reasons beyond hormones but, importantly, there is an estrogen-dependent loss of efficacy related to antipsychotic treatment. Conclusion: Effective clinical intervention is challenging; nevertheless, several promising routes forward are suggested.

Citing Articles

Age and sex differences in outpatient antipsychotic prescriptions for schizophrenia: a claims data study.

Ramin T, Peter J, Schneider M, Heinze M, Riedel O, Langbein S Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 39347833 DOI: 10.1007/s00406-024-01867-z.

Long-acting antipsychotic treatments: focus on women with schizophrenia.

Brissos S, Balanza-Martinez V Ther Adv Psychopharmacol. 2024; 14:20451253241263715.

PMID: 39091697 PMC: 11292690. DOI: 10.1177/20451253241263715.

Knowledge, attitude, and practice toward sleep disorders and sleep hygiene among perimenopausal women.

Shi X, Shi Y, Wang J, Wang H, Li Y Sci Rep. 2024; 14(1):11663.

PMID: 38777871 PMC: 11111451. DOI: 10.1038/s41598-024-62502-4.

Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia.

Galbally M, Wynter K, Siskind D, Correll C, Northwood K, Every-Palmer S CNS Drugs. 2024; 38(7):559-570.

PMID: 38713452 PMC: 11182865. DOI: 10.1007/s40263-024-01089-w.

Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report.

Wang F, Chen J, Guo L, Li Z, Li Z Front Psychiatry. 2023; 14:1276983.

PMID: 37867775 PMC: 10587406. DOI: 10.3389/fpsyt.2023.1276983.

References

Brand B, de Boer J, Sommer I . Estrogens in schizophrenia: progress, current challenges and opportunities. Curr Opin Psychiatry. 2021; 34(3):228-237. PMC: 8048738. DOI: 10.1097/YCO.0000000000000699. View

Rodrigues-Silva C, Semedo A, da Silva Neri H, Vianello R, Galaviz-Hernandez C, Sosa-Macias M . The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia. Neuropsychiatr Dis Treat. 2020; 16:427-432. PMC: 7023876. DOI: 10.2147/NDT.S228103. View

Giordano G, Bucci P, Mucci A, Pezzella P, Galderisi S . Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. Front Psychiatry. 2022; 12:789179. PMC: 8727372. DOI: 10.3389/fpsyt.2021.789179. View

Taylor C, Stewart R, Howard L . Relapse in the first three months postpartum in women with history of serious mental illness. Schizophr Res. 2018; 204:46-54. DOI: 10.1016/j.schres.2018.07.037. View

Joseph S, Nicolson T, Hammons G, Word B, Green-Knox B, Lyn-Cook B . Expression of drug transporters in human kidney: impact of sex, age, and ethnicity. Biol Sex Differ. 2015; 6:4. PMC: 4352278. DOI: 10.1186/s13293-015-0020-3. View

Gillies G, McArthur S . Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev. 2010; 62(2):155-98. PMC: 2879914. DOI: 10.1124/pr.109.002071. View

Ruiz A, Blanco R, Santander J, Miranda E . Relationship between sex differences in onset of schizophrenia and puberty. J Psychiatr Res. 2000; 34(4-5):349-53. DOI: 10.1016/s0022-3956(00)00030-3. View

McCarthy M, Raval A . The peri-menopause in a woman's life: a systemic inflammatory phase that enables later neurodegenerative disease. J Neuroinflammation. 2020; 17(1):317. PMC: 7585188. DOI: 10.1186/s12974-020-01998-9. View

Soldin O, Chung S, Mattison D . Sex differences in drug disposition. J Biomed Biotechnol. 2011; 2011:187103. PMC: 3051160. DOI: 10.1155/2011/187103. View

10.

Simpson E . Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003; 86(3-5):225-30. DOI: 10.1016/s0960-0760(03)00360-1. View

11.

Prior T, Chue P, Tibbo P . Investigation of Turner syndrome in schizophrenia. Am J Med Genet. 2000; 96(3):373-8. DOI: 10.1002/1096-8628(20000612)96:3<373::aid-ajmg26>3.0.co;2-z. View

12.

Dikeocha I, Al-Kabsi A, Miftahussurur M, Alshawsh M . Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. FASEB J. 2022; 36(6):e22350. DOI: 10.1096/fj.202101986R. View

13.

Penninx B, Lange S . Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018; 20(1):63-73. PMC: 6016046. View

14.

Moraga-Amaro R, van Waarde A, Doorduin J, de Vries E . Sex steroid hormones and brain function: PET imaging as a tool for research. J Neuroendocrinol. 2017; 30(2). PMC: 5838537. DOI: 10.1111/jne.12565. View

15.

Wang Q, Dong X, Wang Y, Li X . Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch Womens Ment Health. 2017; 21(1):31-41. DOI: 10.1007/s00737-017-0773-2. View

16.

Barth C, Villringer A, Sacher J . Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci. 2015; 9:37. PMC: 4335177. DOI: 10.3389/fnins.2015.00037. View

17.

Reddy V, McCarthy M, Raval A . Xenoestrogens impact brain estrogen receptor signaling during the female lifespan: A precursor to neurological disease?. Neurobiol Dis. 2021; 163:105596. DOI: 10.1016/j.nbd.2021.105596. View

18.

Davis K, Neinast M, Sun K, Skiles W, Bills J, Zehr J . The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis. Mol Metab. 2013; 2(3):227-42. PMC: 3773827. DOI: 10.1016/j.molmet.2013.05.006. View

19.

Marin R, Diaz M . Estrogen Interactions With Lipid Rafts Related to Neuroprotection. Impact of Brain Ageing and Menopause. Front Neurosci. 2018; 12:128. PMC: 5845729. DOI: 10.3389/fnins.2018.00128. View

20.

Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A, Olajossy M, Wojcierowski J, Landowski J . Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology. 2011; 64(4):202-10. DOI: 10.1159/000327602. View